𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Par-4 inducible apoptosis in prostate cancer cells

✍ Scribed by Sushma Gurumurthy; Vivek M. Rangnekar

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
93 KB
Volume
91
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Prostate cancer is associated with the inability of prostatic epithelial cells to undergo apoptosis rather than with increased cell proliferation. Prostate apoptosis response‐4 (Par‐4) is a unique pro‐apoptotic molecule that is capable of selectively inducing apoptosis in cancer cells when over‐expressed, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. This review discusses the salient functions of Par‐4 that can be harnessed to prostate cancer therapy. © 2004 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Maspin augments proteasome inhibitor-ind
Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells
✍ Xiaohua Li; Di Chen; Shuping Yin; Yonghong Meng; Huanjie Yang; Kristin R. Landis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB

## Abstract Proteasome inhibitors are known to induce apoptosis in a variety of cancer cells. On the other hand, maspin, a non‐inhibitory serine protease inhibitor, is shown to sensitize cancer cells to therapeutic agents that induce apoptosis. We examined the consequence of maspin expression in pr

Pristimerin induces apoptosis by targeti
Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells
✍ Huanjie Yang; Kristin R. Landis-Piwowar; Dayan Lu; Ping Yuan; Lihua Li; G. Prem- 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 1 views

## Abstract Pristimerin is a natural product derived from the __Celastraceae__ and __Hippocrateaceae__ families that were used as folk medicines for antiinflammation in ancient times. Although it has been shown that pristimerin induces apoptosis in breast cancer cells, the involved mechanism of act

CeReS-18 inhibits growth and induces apo
CeReS-18 inhibits growth and induces apoptosis in human prostatic cancer cells
✍ Fattaey, Heideh K.; Quinton, Todd M.; Zhao, Kun; He, Fang; Paulsen, Avelina Q.; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 628 KB

Polypeptide growth factors are positive and negative regulators of prostatic growth and function, and many positive regulators of growth in the prostate have been extensively studied. However, very few inhibitors of prostate cell proliferation have been identified. We have isolated a unique 18-kDa s

Mitotic catastrophe and apoptosis induce
Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells
✍ Francesco Fabbri; Dino Amadori; Silvia Carloni; Giovanni Brigliadori; Anna Tesei 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB

## Abstract Studies performed in different experimental and clinical settings have shown that Docetaxel (Doc) is effective in a wide range of tumors and that it exerts its activity through multiple mechanisms of action. However, the sequence of events induced by Doc which leads to cell death is sti

Silibinin synergizes with mitoxantrone t
Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells
✍ Thomas W. Flaig; Lih-Jen Su; Gail Harrison; Rajesh Agarwal; Leonard Michael Glod 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 265 KB 👁 2 views

## Abstract The purpose of these experiments was to assess the synergistic activity of silibinin with chemotherapy agents in clinical use against prostate cancer. Silybin‐phytosome, a commercially available formulation containing silibinin, has recently been studied in a phase I clinical trial. The

Death receptor-induced cell death in pro
Death receptor-induced cell death in prostate cancer
✍ Natalya V. Guseva; Agshin F. Taghiyev; Oskar W. Rokhlin; Michael B. Cohen 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB

## Abstract Prostate cancer mortality results from metastasis and is often coupled with progression from androgen‐dependent to androgen‐independent growth. Unfortunately, no effective treatment for metastatic prostate cancer increasing patient survival is available. The absence of effective therapi